Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial-Reference-Cited by-同舟云学术

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Published:2020-12-11 Issue:1 Volume:4 Page:206-212
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Cruz Leticia R.¹,Baladrón Idania²,Rittoles Aliusha¹,Díaz Pablo A.²,Valenzuela Carmen³,Santana Raúl¹,Vázquez Maria M.²,García Ariadna¹,Chacón Deyli¹,Thompson Delvin¹,Perera Gustavo¹,González Ariel⁴,Reyes Rafael⁵,Torres Loida⁴,Pérez Jesus¹,Valido Yania¹,Rodriguez Ralysmay¹,Vázquez-Bloomquist Dania M.²,Rosales Mauro²⁶^ORCID,Ramón Ailyn C.²,Pérez George V.²,Guillén Gerardo²,Muzio Verena²,Perera Yasser²⁷,Perea Silvio E.²^ORCID,

Affiliation:

1. Central Hospital “Luis Diaz Soto”, Havana 19130, Cuba

2. Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba

3. Center for Molecular Immunology, Havana 11600, Cuba

4. International Center of Health “La Pradera”, Havana 11600, Cuba

5. National Institute of Oncology and Radiobiology, Havana 10400, Cuba

6. Faculty of Biology, University of Havana, Havana 10400, Cuba

7. China−Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Hunan 425000, China

Funder

British Embassy Havana

Publisher

American Chemical Society (ACS)